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A B S T R A C T
Background: Chronic kidney disease (CKD) is an evolving paradigm for the risk assessment of
cardiovascular diseases. We hypothesized that an advanced stage of CKD may predict the presence of
peripheral arterial disease (PAD).
Methods: Screening for PAD by an ankle-brachial pressure index (ABI) 0.9 was conducted in a
consecutive series of 583 subjects (mean age 68.1  12.9 years, 411 men). Levels of estimated glomerular
ﬁltration rate (eGFR) and factors associated with the presence of PAD were examined.
Results: Sixty patients (10.3%) had PAD and 192 patients (32.9%) had eGFR <60 mL/min/1.73 m2 among
all subjects. In patients with an advanced stage of CKD (stage 3, equivalent to eGFR <60 mL/min/
1.73 m2), high prevalence of PAD (17.2%) and lower ABI levels (1.04  0.18) were observed. Univariate
analyses revealed that PAD was associated with an advanced stage of CKD [odds ratio (OR) 1.850, 95%
conﬁdence interval (CI) 1.322–2.588, p < 0.001], as well as age, male gender, systolic blood pressure, and
hemoglobin A1c. Multivariate logistic regression analyses revealed that PAD was independently predicted by
the CKD stages (OR 1.498, 95% CI 1.011–2.220, p = 0.044, adjusted for covariates).
Conclusions: An advanced stage of CKD is independently and signiﬁcantly associated with the presence
of PAD. Targeted screening with ABI measurement can be beneﬁcial in patients with CKD.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atherosclerosis is still a leading cause of death in industrialized
countries. The Framingham Heart Study [1] and the NIPPON
DATA80 [2] research have demonstrated that the progression of
systemic atherosclerosis leads to an accumulation of cardiovascu-
lar risk factors and may result in the development of polyvascular
disease. Based on these large-scale cohort studies, the Framingham
Risk Sore [1] and the NIPPON DATA80 chart [2] for the Japanese
population have been developed to predict an individual’s risk of a
future coronary artery event or stroke.
Lower-extremity peripheral arterial disease (PAD) can be a
manifestation of systemic atherosclerosis [3,4] and the morbidity
has been associated with an elevated risk of cardiovascular disease.* Corresponding author at: Department of Cardiovascular Medicine, Shinshu
University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
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http://dx.doi.org/10.1016/j.jjcc.2015.01.011
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsAlthough PAD screening for high-risk patients and early treatment
intervention are essential, there is still no system which has been
established for predicting the presence of PAD by calculating
traditional risk factors or biomarkers. In fact, 12.3% of patients who
have low cardiovascular risk with Framingham scores have shown
an abnormal ankle brachial index (ABI) [5], which represents the
presence of PAD [3,6,7].
Recent studies have demonstrated that individuals with
chronic kidney disease (CKD) are more likely to develop
atherosclerotic cardiovascular diseases [8–11]. Importantly, the
comorbidity of PAD and CKD is strongly indicative of an individual
at high risk [12]. Although ethnic-speciﬁc variations in the
prevalence of PAD have been reported [13,14], large-scale clinical
studies from Asian population are limited. The morbidity of PAD in
the general Japanese population aged 40 years or over is 1.47% [15]
and that in diabetic patients is 7.6% [16]. Markedly high PAD
prevalence of 23.8% [17] and even 47.2% [18] have been reported in
Japanese patients undergoing hemodialysis; however, the associ-
ation between PAD and CKD has not been fully investigated. The
aim of this study was to evaluate the prevalence of PAD and its reserved.
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low levels of estimated glomerular ﬁltration rate (eGFR) can
predict the presence of PAD.
Materials and methods
Study patients
Data were collected from a consecutive series of 583 patients
examined with ABI on admission. These patients were hospitalized
for examination and/or treatment of the following cardiovascular
diseases: 54.8% were ischemic heart disease, 18.5% were heart
failure due to valvular and/or myocardial disease, and 20.4% were
for arrhythmia or others. We excluded patients with a cardiovas-
cular emergency, unstable coronary artery disease, or decom-
pensated heart failure, and also patients on hemodialysis. The
study was performed in accordance with the Declaration of
Helsinki and with Good Clinical Practice. Patients were managed
according to the recommended guidelines of the Japanese
Circulation Society. Data were analyzed anonymously, because
this study was performed retrospectively without informed
consent.
ABI measurement
The systolic blood pressure (BP) in the right and left brachial
arteries, dorsalis pedis arteries, and posterior tibial arteries was
measured using Form (Omron Colin, Tokyo, Japan) after the patient
had rested in the supine position for at least 10 min. For each leg,
the higher of the BP values in the dorsalis pedis and posterior tibial
arteries was divided by the higher of the left and right arm brachial
BP values, and the lower of the two results (right and left leg) was
used as ABI in all analyses [19]. The presence of PAD was deﬁned by
an ABI 0.9 [3,20].
Renal function
Levels of eGFR of all patients were calculated from the
serum creatinine levels, using the following equation established
by the Japanese Society of Nephrology: eGFR (mL/min/1.73 m2) =
194  serum creatinine level1.094  age0.287 (0.739 if female)
[21]. The stages of CKD were classiﬁed based on the levels of eGFR:
stage 1 (eGFR 90 mL/min/1.73 m2), stage 2 (eGFR 60–89 mL/min/Table 1
Clinical characteristics of the study population and categories of renal function.
Characteristics All (n = 583) eGFR <60 m
(n 
Age, years 68.1  12.9 73.7
Male, n (%) 411 (70.5) 152 (
ABI 1.08  0.17 1.0
ABI 0.9, n (%) 60 (10.3) 33 (
eGFR, mL/min/1.73 m2 68.86  23.52 46.2
Hypertension, n (%) 387 (66.4) 146 (
Dyslipidemia, n (%) 269 (45.1) 100 (
Diabetes, n (%) 169 (29.0) 71 (
Smoking, n (%) 286 (49.1) 104 (
Hyperuricemia, n (%) 78 (13.4) 44 (
Family history, n (%) 117 (20.1) 46 (
Ischemic heart disease, n (%) 320 (54.8) 117 (
Vascular disease, n (%) 102 (17.5) 37 (
Arrhythmia, n (%) 119 (20.4) 36 (
Valvular disease, n (%) 45 (7.7) 14 (
Cardiomyopathy, n (%) 34 (5.8) 8 (
Heart failure, n (%) 29 (5.0) 12 (
eGFR, estimated glomerular ﬁltration ratio; ABI, ankle-brachial index.1.73 m2), stage 3 (eGFR 30–59 mL/min/1.73 m2), stage 4 (eGFR 15–
29 mL/min/1.73 m2), and stage 5 (eGFR < 15 mL/min/1.73 m2).
Coronary risk factors
We examined low-density lipoprotein cholesterol (LDL-C) and
hemoglobin A1c (HbA1c). Clinical characteristics of the study
population were derived from interviews or history of or treatment
for the morbidities with the following criteria: hypertension was
blood pressure 140/90 mmHg, dyslipidemia was LDL-C
140 mg/dL, and/or triglycerides 150 mg/dL, diabetes mellitus
was HbA1c 6.1% of the National Glycohemoglobin Standardiza-
tion Program, and hyperuricemia was uric acid 7.0 mg/dL in
accordance with screening criteria of each clinical guideline.
Statistical analysis
Categorical variables were expressed as absolute frequency and
relative frequency (percentage) and compared using the x2 test.
Continuous variables were expressed as mean  standard deviation
and were compared using the Mann–Whitney test. One-way analysis
of variance (ANOVA) with the Kruskal–Wallis test and Dunnett’s
multiple comparisons test was used to compare ABI levels between
CKD stages. The magnitude of the association between patient
characteristics and the presence of PAD was quantiﬁed in terms of the
odds ratio (OR) and the 95% conﬁdence interval (CI) using univariate
logistic regression analyses. Multiple logistic regression analyses
were then performed with adjustments for signiﬁcant parameters,
apart from multicollinear variables, to determine the subset of
independent variables for predicting PAD. We assessed the diagnostic
accuracy of variables by using a receiver operating characteristic
(ROC) curve [22]. A p-value <0.05 was considered statistically
signiﬁcant. All statistical analyses were performed using IBM SPSS
Statistics 18 (IBM Co., Armonk, NY, USA).
Results
Table 1 summarizes the clinical characteristics of the study
population and the categories of renal function. The study
population consisted of 583 hospitalized patients (mean
68.1  12.9 years, 411 men). Sixty patients (10.3%) had PAD and
192 patients (32.9%) showed renal insufﬁciency, deﬁned as a eGFR
level <60 mL/min/1.73 m2. The prevalence of hypertension, dyslipi-
demia, diabetes, smoking, and hyperuricemia in the study populationL/min/1.73 m2
= 192)
eGFR 60 mL/min/1.73 m2
(n = 391)
p-Value
  8.9 65.4  13.6 <0.001
79.2) 259 (66.2) 0.001
4  0.18 1.11  0.15 <0.001
17.2) 27 (7.0) <0.001
6  11.68 80.04  19.40 <0.001
76.0) 241 (61.6) 0.001
52.1) 169 (43.2) 0.049
37.0) 98 (25.1) 0.003
54.2) 182 (46.5) 0.090
22.9) 34 (8.7) <0.001
24.0) 71 (18.2) 0.124
60.9) 203 (51.9) 0.046
19.3) 65 (16.6) 0.445
18.3) 83 (21.2) 0.467
7.3) 31 (7.9) 0.774
4.2) 26 (6.6) 0.224
6.3) 17 (4.3) 0.328
Table 2
Univariate and multivariate adjusted odds ratios (95% conﬁdence intervals) of
peripheral arterial disease, on the basis of an ankle-brachial index 0.9.
Variable Univariate OR
(95% CI)
p Multivariate OR
(95% CI)
p
CKD stage 1.850 (1.322–2.588) <0.001 1.498 (1.011–2.220) 0.044
Age 1.043 (1.016–1.070) 0.002 1.036 (1.006–1.068) 0.020
Male 2.566 (1.234–5.337) 0.012 2.587 (1.192–5.617) 0.016
Systolic
BP
1.021 (1.007–1.035) 0.002 1.020 (1.006–1.035) 0.004
LDL-C 1.004 (0.996–1.012) 0.361
HbA1c 1.497 (1.175–1.906) <0.001 1.427 (1.098–1.854) 0.008
Multivariate analysis was adjusted for CKD stage, age, male gender, systolic BP,
and HbA1c.
OR, odds ratio; CI, conﬁdence interval; CKD, chronic kidney disease; BP, blood
pressure; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c.
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level of all the patients was 1.08  0.17. Patients with eGFR <60 mL/
min/1.73 m2 had a signiﬁcantly lower ABI compared to those with
eGFR 60 mL/min/1.73 m2 (1.04  0.18 vs. 1.11  0.15, respectively,
p < 0.001). Patients with eGFR <60 mL/min/1.73 m2 were predomi-
nantly male, older, and had a signiﬁcantly higher prevalence of
hypertension, dyslipidemia, diabetes, and hyperuricemia, compared
to those with eGFR 60 mL/min/1.73 m2 (Table 1).
The major pre-existing cardiovascular diseases among all
patients were ischemic heart disease (54.8%), vascular disease
(17.5%), arrhythmia (20.4%), valvular heart disease (7.7%), and
cardiomyopathy (5.8%). There was no difference in background
diseases between patients with eGFR 60 and those with eGFR
<60 mL/min/1.73 m2, except for the high prevalence of ischemic
heart disease in patients with eGFR <60 mL/min/1.73 m2 (60.9% vs.
51.9%, p = 0.046).
The relationship between ABI levels and CKD stages is
summarized in Fig. 1. A signiﬁcant difference in ABI levels was
observed among CKD stages (p = 0.0002). ABI of CKD stage
3 patients was 1.040  0.174 and of stage 4 was 0.984  0.242,
and these levels were signiﬁcantly lower as compared with
1.105  0.130 of stage 1 patients (p = 0.008 and 0.010, respectively).
ABI of stage 5 patients (1.105  0.139) should be considered as a
reference value, because of the small number of patients after
exclusion of hemodialysis. The advanced stage of CKD was
signiﬁcantly associated with the presence of PAD (OR 1.850, 95% CI
1.322–2.588, p < 0.001), as was demonstrated by univariate logistic
regression analysis; other associated factors were older age, male
gender, high systolic BP, and HbA1c (Table 2). Multivariate logistic
regression analyses with adjustments for CKD stage, age, gender,
systolic BP, and HbA1c showed that CKD stage (OR 1.498, 95% CI
1.011–2.220, p = 0.044), as well as male gender, and HbA1c levels
were independently and signiﬁcantly associated with the presence of
PAD (Table 2). Systolic BP and older age also showed a weak
association with PAD (Table 2).
The area under the ROC curves of eGFR and HbA1c were 0.634
(95% CI 0.560–0.708, p < 0.001) and 0.638 (95% CI 0.563–0.713,
p < 0.001), respectively. The optimal cutoff value for eGFR was
60.28 mL/min/1.73 m2, with sensitivity and speciﬁcity of 69.0%
and 56.7%, respectively (Fig. 2).
Discussion
This study revealed a high PAD prevalence of 17.2% in patients
with eGFR levels <60 mL/min/1.73 m2 as compared with that of
7.0% in patients with eGFR 60 mL/min/1.73 m2. Importantly, anSt
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Fig. 1. Relationship between ankle-brachial index (ABI) levels and stages of chronic
kidney disease. Differences among stages were signiﬁcant (p = 0.0002) and patients
in stages 3 and 4 had signiﬁcantly lower ABI levels as compared with that of stage
1. The whiskers show minimum to maximum range, the bottom and top of each box
shows the ﬁrst and third quartiles, and the band inside the box shows the median.advanced stage of CKD was a strong risk predictor for the
cormorbid PAD (OR 1.498); other predictors were male gender (OR
2.587), HbA1c (OR 1.427), and high systolic BP (OR 1.020).
Although ABI measurement is a noninvasive and effective means of
diagnosing PAD [23], with high sensitivity and speciﬁcity
[3,6,24,25], clinicians should select candidates for PAD screening
with minimum unnecessary workups because the morbidity of
PAD is low (2–4%) in healthy individuals [26,27]. Based on the
results of this study and the usefulness of ABI for identifying PAD,
we can conclude that ABI screening is warranted especially in
patients with an advanced stage of CKD.
Studies that calculated GFR using the Cockroft–Gault equation
[28] or the Modiﬁcation of Diet in Renal Disease formula [29] have
demonstrated a high PAD prevalence of 37.4–41.9% in patients
with eGFR < 60 mL/min/1.73 m2, as compared with 22.3–24.3% in
patients with eGFR 60 mL/min/1.73 m2 [12,30]. In this study, we
obtained comparable results using a Japanese equation for
estimating GFR, which was derived from a Japanese population
study [21]. The use of a race-speciﬁc equation for eGFR is
important, because the Japanese skeletal muscle mass is less than
that of North Americans, as has been demonstrated by magnetic
resonance imaging analyses [31,32].
Patients with eGFR <60 mL/min/1.73 m2 in this study were
signiﬁcantly older and had a high prevalence of risk factors such as
hypertension and hyperuricemia; nevertheless, the advanced stage
of CKD was independently and signiﬁcantly associated with the
presence of PAD, after adjustments for age and other factors. The
signiﬁcant OR of CKD in predicting comorbid PAD is consistent100% - Specifi cit y% 
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Fig. 2. Receiver operating characteristic (ROC) curve of estimated glomerular
ﬁltration rate (eGFR) for prediction of peripheral arterial disease. The cutoff value
for eGFR at 60.28 mL/min/1.73 m2 had sensitivity of 69.0% and speciﬁcity of 56.7%.
AUC, area under the ROC curve.
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p = 0.049) [30], Baber et al. (OR 1.58, 95% CI 1.09–2.29, p < 0.05)
[33], and Wu et al. (OR 1.43, 95% CI 0.98–2.09, p = 0.07) [34].
In addition to an advanced stage of CKD, the presence of PAD
was associated with male gender, and high systolic BP and HbA1c
levels. Among Japanese PAD patients enrolled in the REACH
registry (n = 627), the majority were males (83.7%) and had a
higher prevalence of hypertension (77.8%) than did patients with
coronary artery disease (68.0%) or cerebrovascular disease
(74.4%) [35]. The results of the present study, in keeping with
the Japanese REACH population, suggested that hypertension
could explain, at least in part, the association between CKD and
PAD.
The area under the ROC curves to predict PAD suggested that
the sensitivity and speciﬁcity of eGFR were similar to those of
HbA1c. In addition to the known risk of diabetes [3,36,37], levels of
eGFR below 60 mL/min/1.73 m2 can be a better predictor of PAD;
the cutoff level is identical to that reported in TASC II and other
previous studies [3,30,33]. A recent report has clearly demonstrat-
ed that patients with PAD accompanied with CKD are at
particularly high risk for all-cause and cardiovascular mortality
[12]. In fact, in this study we observed a higher prevalence of
ischemic heart disease in patients with both PAD and CKD than in
the other patients (62.0% vs. 54.6%, respectively). Early screening
for PAD and early treatment intervention are, therefore, essential
in CKD patients, and may contribute to preventing future
cardiovascular events.
Our study had certain limitations. First, it was a single-center
study and the number of patients was relatively small. Second,
there could be sample bias toward a high prevalence of pre-
existing cardiovascular diseases in the hospitalized patients in
this study, compared with the general Japanese population [38–
41]. Thus, the study population might have had an atypically
high prevalence of PAD. Third, the disease progression and long-
term patient outcomes were not analyzed, because of the limited
series of follow-up data. Fourth, we could not determine any
pathophysiological mechanism for the association between PAD
and CKD. This association could be explained in part by new
biomarkers for premature atherosclerosis [42,43], as well as by
traditional cardiovascular risk factors. In addition, progressive
deterioration of renal function in CKD can be associated with
the accumulation of uremic toxins, which stimulate oxidative
stress and inﬂammation, and in turn contribute to endothelial
dysfunction and the progression of atherosclerosis [44–46]. Fur-
ther studies are needed to identify the mechanism and factors
that affect the long-term prognosis of patients with PAD and
CKD.
Conclusion
An advanced stage of CKD with an eGFR cutoff level of
<60 mL/min/1.73 m2 was an independent and signiﬁcant pre-
dictor for comorbid PAD in Japanese patients. PAD screening
with ABI measurement can thus be beneﬁcial for patients with
CKD.
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